About US
Contact us
-
Genzyme announces Japanese approval of Synvisc viscosupplement for OA knee pain reliefGenzyme Corporation (Nasdaq: GENZ) announced today that Japan's Ministry of Health, Labour and Welfare has approved Synvisc® (hylan G-F 20; 3 x 2 mL), indicated for the treatment of osteoarthritis2010/9/21
-
Elias Shaker to sell Generex's novel consumer productsGenerex Biotechnology Corporation (Nasdaq: GNBT), (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into2010/9/21
-
Preparing for Mandatory Electronic Submission of Drug Establishment Registration and Drug Listing InformationPreparing for Mandatory Electronic Submission of Drug Establishment Registration and Drug Listing Information Prepared by Gina A. Ross and Greg A. Onyszchuk, Ph.D. Introduction United States2010/9/20
-
Johnson & Johnson in talks to buy CrucellJohnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst2010/9/20
-
CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine developmentCytoGenix, Inc. (Pink Sheets:CYGX) today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furtherin2010/9/19
-
PharmaZell Continues Expansion of Pharmaceutical Manufacturing Capacity in IndiaVizag, India (September 20, 2010) – PharmaZell GmbH, a European Contract Manufacturing Organization for active pharmaceutical ingredients and advanced intermediates, has once again expanded its manu2010/9/19
-
GSK, Genmab to refocus on ofatumumab development program in autoimmune indicationsGlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN); Following the 1st July announcement by GSK and Genmab of anamendment to the collaborative agreement for ofatumumab in which GSK assumeddevelopmen2010/9/17
-
NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC ConferenceNovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infec2010/9/17
-
China International Medical Device Regulatory Forum 2010 held in BeijingIn order to promote the exchange on Chinese and international medical device regulations and company the formulation and revision of the Regulations for the Supervision and Administration of Medica2010/9/16
-
SFDA Deputy Commissioner Wu Zhen meets CEO of the Danish Medicines AgencyOn the morning of September 9, 2010, Wu Zhen, Deputy Commissioner of the State Food and Drug Administration (SFDA), met the visiting Jytte Lyngvig, Chief Executive Officer of the Danish Medicines A2010/9/16